The power of RNAi to create new medicines

We are a pioneer in the development of novel drugs based on RNA interference (RNAi) technology.

Founded in 2006 and part of the PharmaMar group (BME: PHM), our mission is to build a solid and sustainable business and become a leader in the development of RNAi-based products.

We develop new drugs using artificial intelligence with the aim of improving the quality of life of patients.

We are proud to be a company with a highly innovative culture that spans from drug discovery through the entire product life cycle.


Technology at the service of Health

Through science and innovative medicine, Sylentis aims to become one of the leading companies specializing in the discovery, development and manufacture of products based on RNAi technology for the treatment of diseases with a high social impact.

Our ambition is to become the most highly valued company in the industry by patients and healthcare professionals. At Sylentis, we aim to increase our competitiveness as a pharmaceutical company by advancing the therapeutic areas in which we research and develop drugs.

Our values

Certifications and awards

Madrid Excelente

Officially recognized by the guarantee mark from the Community of Madrid, “Madrid Excelente”, which certifies quality and excellence in company management.

GMP (Good Manufacturing Practice) certified

Sylentis holds a Certificate of Compliance with Good Manufacturing Practices from the Spanish Agency for Medicines and Health Products.